Public Release: 

Stealth-cap technology for light-emitting nanoparticles

Helmholtz-Zentrum Dresden-Rossendorf

IMAGE

IMAGE: Nanoparticles in the blood: The stealth-cap prevents blood components from adhering. The surface has been cross-linked by UV radiation (enlarged image section) and is therefore stable in biological systems.... view more 

Credit: HZDR/Sahneweiss/istockphoto.com/Thomas-Soellner/Molekuul

A team of scientists from the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), in collaboration with researchers from Monash University Australia, has succeeded in significantly increasing the stability and biocompatibility of special light-transducing nanoparticles. The team has developed the so-called "upconverting" nanoparticles that not only convert infrared light into UV-visible light, but also are water-soluble, remain stable in complex body fluids such as blood serum, and can be used to store medications. They have created a tool that could potentially make the fight against cancer significantly more effective. The researchers recently published their results in the journal Angewandte Chemie (DOI: 10.1002 / anie.201811003).

Nanoparticles are tiny structures, typically less than 100 nanometers in size, which is about 500 to 1000 times smaller than the thickness of a human hair. Such materials are receiving increasing attention for biomedical applications. If equipped with appropriate properties, they can reach almost any tissue in the human body via the bloodstream - turning into perfect body probes.

It has been known for some years that the distribution of nanoparticles in the body is essentially determined by their size and surface properties. Dr. Tanmaya Joshi at HZDR's Institute for Radiopharmaceutical Cancer Research says, "Upconverting nanomaterials are of great interest for biomedical imaging". "When stimulated with infrared light they can send out bright blue, green, or red signals. If we succeed in navigating such nano-probes to diseased tissues, it can be particularly useful for cancer diagnosis", the team's photochemist, Dr. Massimo Sgarzi, added.

However, these light upconverters show poor solubility in water or tissue fluids - a must to have feature before any diagnostic or therapeutic use could be imagined. For the HZDR team this was not a hindrance, but rather a challenge: "We used a unique polymer mixture to cover the particles," says Dr. Joshi, who joined HZDR in 2017 from Monash University, as a Humboldt Fellow. Adding this protective cover makes the light-transducing nanoparticles biocompatible. The biologist Dr. Kristof Zarschler adds: "The upconverters are now water-soluble and even have a neutral surface charge. Our research shows that this new cover can almost completely prevent the body's own substances (present in the blood serum) from binding to the particles. In other words, the nanoparticles now seem to wear an invisibility cloak. This, we believe, will help to avoid their recognition and elimination by phagocytes of the immune system. "

In order to keep the new nano-probes stable for weeks in a complex biological environment, the scientists photochemically link the components of the protective shell with each other: "We simply irradiated our nanoparticles with UV light. This creates additional bonds between the molecular components constituting the protective cover - much alike sewing together the individual parts of the cloak of invisibility with the help of light, "explains the PhD student, Anne Nsubuga. She further adds, "This shell is only a few nanometers thick, and may even be used for hiding other substances, for example, cancer drugs, which could be later on released in the tumour and destroy it."

Following this breakthrough, the team now intends to validate their current results in living organisms: "For this, we first have to carry out strictly regulated and ethically acceptable experiments on animals. Only when our stealth-cap technology works on these without any side effects, their medical potential will be explored in detail and their application on the patients can be considered", explains the group leader Dr. Holger Stephan cautiously.

###

Publication: Publikation: Anne Nsubuga, Kristof Zarschler, Massimo Sgarzi, Bim Graham, Holger Stephan, Tanmaya Joshi: „Towards Utilising Photocrosslinking of Polydiacetylenes (PDAs) for the Preparation of "Stealth" Upconverting Nanoparticles (UCNPs)", Angew. Chem. 2018, DOI: 10.1002/anie.201811003 (Link: https://doi.org/10.1002/anie.201811003 )

For more information:

Dr. Tanmaya Joshi
Institute of Radiopharmaceutical Cancer Research at HZDR
Phone +49 351 260 - 2437 | Email: t.joshi@hzdr.de">t.joshi@hzdr.de

Media contact:

Dr. Christine Bohnet | Head of HZDR Communications
Phone +49 351 260 - 2450 or +49 160 969 288 56 | Email: c.bohnet@hzdr.de">c.bohnet@hzdr.de
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) | http://www.hzdr.de
Bautzner Landstr. 400 | 01328 Dresden | Germany

The Helmholtz-Zentrum Dresden-Rossendorf (HZDR) carries out research in the areas of Energy, Health and Matter. The following questions are key:

* How can energy and resources be utilized in an efficient, safe, and sustainable way?

* How can malignant tumors be more precisely visualized, characterized, and more effectively treated?

* How do matter and materials behave under the influence of strong fields and in smallest dimensions?

The HZDR operates large-scale infrastructures that are also available to external users, such as the Ion Beam Center (IBC), the Dresden High Magnetic Field Laboratory (HLD) and the Elbe Center for High-Power Radiation Sources.

HZDR is a member of the Helmholtz Association and has five sites (Dresden, Freiberg, Grenoble, Leipzig, Schenefeld near Hamburg) with almost 1,200 members of staff, of whom about 500 are scientists, including 150 Ph.D. candidates.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.